Unable to resolve these hold issues without substantive feedback from the FDA, MAPS submitted a formal “Type A Meeting Request” on April 20, 2020. This formal meeting request asked the FDA reviewers to meet with MAPS to discuss the hold issues in an effort to resolve the concerns and facilitate the removal of the clinical hold for Study MT2.